Kategoria: General Medical Discoveries (EN)

Researchers developed a locally deployed medical AI system that not only proposes a diagnosis but also checks how consistently it reaches the same answer across repeated runs. On two retrospective clinical-reasoning benchmarks derived from MIMIC-IV data, the agent achieved diagnostic accuracy of 90.04% and 83.8%. When a very high consistency threshold was used, 49.4% of cases were retained for potential autonomous handling, with 98.9% diagnostic accuracy in that selected subset; less stable cases were deferred for human review.

For an orthopaedic surgeon assessing future clinical AI tools, this is an interesting approach to building a practical “safety brake” into such systems, but it is not evidence that such a system is ready to make independent decisions for real patients. All evaluations were retrospective simulations, the main benchmarks came from one data environment, and the threshold depended on the technical configuration. Prospective studies, independent validation and dedicated safety and bias assessments are still needed.

Source: Zhang L, Wölflein G, Ferber D et al. On-premise medical AI agents for reliable clinical decision-making. Nature Medicine. Published online 15 September 2026. DOI: 10.1038/s41591-026-04609-x. Full open-access article reviewed; source checked 16 September 2026.

← Back to General Medical Discoveries

Polish version: Medyczne AI z „hamulcem bezpieczeństwa”: obiecujące wyniki w symulowanych przypadkach

Content prepared by: Tomasz Poboży - orthopaedic surgeon.

Researchers measured 2,904 proteins in blood samples taken at about 12 weeks of pregnancy and found that low levels of isthmin-2 (ISM2) were the strongest protein signal associated with later preeclampsia or fetal growth restriction. The association was reproduced in two independent cohorts. Laboratory experiments with human trophoblast stem cells also showed that reducing ISM2 impaired the invasive behaviour needed for normal placental development, providing biological support for the clinical observation.

An orthopaedic surgeon reading research from other specialties should note the study design: this was observational research in pregnant women supplemented by laboratory experiments, not a trial of a new treatment. ISM2 may eventually contribute to earlier risk assessment or become a research target for prevention, but it is not yet a diagnostic test or an available therapy. The cohorts were predominantly from northern Europe, so the findings need confirmation in larger and more diverse populations.

---

Source: Miao R, Gong S, Sovio U, et al. Isthmin-2 is a first-trimester predictor of preeclampsia and fetal growth restriction. Nature Medicine. Published online 1 September 2026. DOI: 10.1038/s41591-026-04573-6. Verified 16 September 2026. Access: full open-access article and PubMed record; no correction or retraction was identified in the sources checked.

Polish version · More General Medical Discoveries

Content prepared by: Tomasz Poboży - orthopaedic surgeon.

Researchers have reported a patient with end-stage kidney disease who received a gene-edited pig kidney and remained independent of dialysis for 271 days. After months of initially stable function, microvascular injury developed and the xenograft eventually failed and was removed. Eighty-two days later the patient received a human kidney, which functioned immediately; during 231 days of follow-up, the investigators found no evidence that the pig kidney had caused clinically significant sensitisation that would hinder the human transplant. The case suggests that a gene-edited pig kidney might one day serve as a temporary bridge for selected patients facing a long wait for a human organ. An orthopaedic surgeon following advances in transplantation should distinguish a case report from established care: this was the first recipient in a planned three-patient study under an FDA expanded-access programme, not an established treatment, so durability, safety and rejection mechanisms still need to be studied in more people.

---

Source: Riella LV, Borges TJ, Rosales IA, et al. Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study. The Lancet. First published online 3 September 2026. DOI: 10.1016/S0140-6736(26)01295-X; checked 16 September 2026; access: full abstract and bibliographic record via PubMed and the publisher link; the publisher’s full text was not available in the access used.

← Back to General Medical Discoveries

Polish version

Content prepared by: Tomasz Poboży - orthopaedic surgeon.

General Medical Discoveries · Human observations plus laboratory and animal studies

Researchers have described a newly identified tick-borne virus, Asian longhorned tick nairovirus (ALTNV), in people with fever after tick exposure in China. Among 3,163 such patients, ALTNV RNA or IgM antibodies were detected in 10.4%; 56 patients had ALTNV infection without concurrent Dabie bandavirus infection, and all of them recovered without sequelae. The virus was isolated from patient samples, detected in Haemaphysalis longicornis ticks, and experimental work showed that these ticks could transmit it to mice. Among 38 people coinfected with ALTNV and Dabie bandavirus, respiratory symptoms and renal impairment were more frequent and 7 patients died, but an orthopaedic surgeon or any other clinician interpreting these findings should note that this observational comparison cannot establish that ALTNV itself caused the greater severity. This is not a new treatment or a ready-to-use screening test; the main significance is recognition of another potential tick-borne human pathogen that now requires further epidemiological surveillance.

Source: Zhang X-A, Liu B, Wu S-Q, et al. A Zoonotic Orthonairovirus from Febrile Patients in China. New England Journal of Medicine. Published online 2 September 2026;395:929–931. DOI: 10.1056/NEJMc2602496. Checked 16 September 2026; access: full article, supplementary material and PubMed record. No correction or retraction was found in the records checked.

← More General Medical Discoveries

Polish version

Content prepared by: Tomasz Poboży - orthopaedic surgeon.

General Medical Discoveries · Large randomised phase 3 trial

The LAIS trial tested intravenous loberamisal, a drug being studied to protect nerve cells and support recovery after an ischaemic stroke. Among 997 patients treated within 48 hours of symptom onset, full or near-full functional recovery at 90 days was achieved by 69.7% of patients receiving loberamisal and 56.3% receiving placebo. For an orthopaedic surgeon following research on recovery of function, the result is encouraging, but the trial was conducted entirely in China, excluded patients treated with endovascular thrombectomy, and several secondary outcomes did not differ between groups. The findings therefore need confirmation in other populations and care settings before broader clinical use can be established.

Source: Li S, Feng B, He D, et al. Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical Trial. JAMA. Published online 10 September 2026. DOI: 10.1001/jama.2026.16557. Checked 16 September 2026; access: full text on the JAMA website and PubMed record. No correction or retraction was found in the records checked.

← More General Medical Discoveries

Polish version

Content prepared by: Tomasz Poboży - orthopaedic surgeon.

General Medical Discoveries · Large randomised clinical trial

In people with STEMI who also have disease in several coronary arteries, clinicians often need to decide which remaining narrowings should be treated. In the international AIR-STEMI trial, 1,823 patients were randomly assigned after successful treatment of the culprit lesion to complete revascularisation guided either by functional coronary angiography or by conventional angiography. After a median follow-up of 17.9 months, the composite outcome of death, another myocardial infarction, stroke or TIA, or ischaemia-driven repeat revascularisation occurred in 8.9% of the physiology-guided group and 13.7% of the angiography-guided group. The combined safety outcome of contrast-associated acute kidney injury or major bleeding was also less frequent with the functional strategy. An orthopaedic surgeon reading this large human randomised trial should note that it applies to a specific group of patients after STEMI and does not mean that a patient can decide independently whether a coronary narrowing needs a stent.

Source: Biscaglia S, Erriquez A, Colaiori I, et al. Complete Revascularization Guided by Functional Coronary Angiography in STEMI. New England Journal of Medicine. Published online 29 August 2026; 2026;395:972–982. DOI: 10.1056/NEJMoa2605373. PMID: 42670979. Source record rechecked 16 September 2026; this patient summary uses the publisher abstract and bibliographic data from NEJM and PubMed.

Polish version · Back to General Medical Discoveries

Content prepared by: Tomasz Poboży - orthopaedic surgeon.

KRAS G12D is found in some pancreatic, lung and colorectal cancers and has long been difficult to target directly. In a phase 1 trial, 74 previously treated patients with advanced KRAS G12D-mutant solid tumours received the oral drug GFH375. Confirmed tumour shrinkage was seen in about one third of evaluable patients with pancreatic ductal adenocarcinoma or non-small-cell lung cancer. An orthopaedic surgeon following early drug-development studies should distinguish a response signal from comparative evidence: this is an encouraging early signal, but the study had no control group, so it does not yet show how GFH375 compares with standard treatment or whether it improves survival. Serious treatment-related adverse events also occurred, including one treatment-related death from septic shock. The phase 2 part of the study is ongoing.

Source: Ai X, Song Z, Wu L, et al. Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRAS^G12D mutations: a phase 1 trial. Nature Medicine. Published online 15 September 2026. DOI: 10.1038/s41591-026-04559-4. ClinicalTrials.gov: NCT06500676. Source record rechecked 16 September 2026; the original Polish summary was based on the publisher abstract and metadata and did not analyse the paywalled full text. Evidence stage: phase 1; phase 2 expansion is ongoing.

Polish version · Back to General Medical Discoveries

Content prepared by: Tomasz Poboży - orthopaedic surgeon.

General Medical Discoveries · Human study — phase 3 / therapy approved in the United States

Glycogen storage disease type Ia is a rare genetic disorder that makes it difficult to maintain blood glucose during periods without food, so many patients need regular doses of uncooked cornstarch. In a randomised phase 3 trial, a single dose of DTX401 (pariglasgene brecaparvovec) reduced daily cornstarch intake after 48 weeks by about 41%, compared with 10% with placebo, and the trial reported that its prespecified measures of glycaemic control were maintained. The FDA review was more cautious: treated participants had numerically more hypoglycaemia and slightly more time below glucose thresholds, so reduced cornstarch use should not be interpreted as complete normalisation of glucose regulation. An orthopaedic surgeon following advances in gene therapy should note that the trial was small and that longer follow-up is still needed to understand the durability of benefit and long-term safety. The FDA granted accelerated approval in the United States on 19 August 2026 for patients aged 8 years and older, based on reduced cornstarch intake; continued approval may depend on confirmatory evidence, and regulatory status and availability may differ in Europe.

Source: Mitchell JJ, Abdenur JE, de Boer F, et al. Phase 3 Randomized Trial Results of DTX401 AAV Gene Therapy for the Treatment of GSDIa. Journal of Inherited Metabolic Disease. First published 31 August 2026. DOI: 10.1002/jimd.70241; PubMed PMID 42674977. The open-access full text and bibliographic record were checked on 15 September 2026; no correction or retraction was found in the records checked. U.S. regulatory status and additional safety context were checked against the FDA approval materials for Genglycos (pariglasgene brecaparvovec-opnr), 19 August 2026.

Polish version · Back to General Medical Discoveries

Content prepared by: Tomasz Poboży - orthopaedic surgeon.

Type 1 narcolepsy is driven by loss of orexin signalling, which helps regulate wakefulness and sleep. In two large randomised phase 3 trials, oveporexton — an oral, selective orexin receptor 2 agonist — was compared with placebo. After 12 weeks, treated participants stayed awake longer in formal testing, reported less daytime sleepiness and had fewer cataplexy attacks. Increased urinary frequency and transient insomnia were among the most common adverse effects. This is no longer only an experimental programme: the FDA approved oveporexton (Orzeyful) for adults with type 1 narcolepsy in the United States on 5 August 2026, although an orthopaedic surgeon or any other physician reading the report should distinguish the research results from availability, which still depends on country-specific regulatory decisions.

Source: Dauvilliers Y, Mignot E, Antczak J, et al. Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials. New England Journal of Medicine. Published online 9 September 2026. DOI: 10.1056/NEJMoa2601598; PubMed PMID 42714024. Source details and the published results were checked on 15 September 2026 against the NEJM article page and PubMed record; no correction or retraction was found in the checked records. U.S. regulatory status: FDA approval announcement, 5 August 2026.

Polish version · Back to General Medical Discoveries

Content prepared by: Tomasz Poboży - orthopaedic surgeon.

General Medical Discoveries · Human study — phase 1/2a

Researchers tested ARO-RAGE, an experimental inhaled siRNA designed to silence RAGE in lung cells, a protein involved in sustaining inflammatory signalling. In this first-in-human study, the treatment was given to healthy volunteers and people with asthma; it reached its pulmonary target and produced marked reductions in soluble RAGE (sRAGE) in the airways and blood. ARO-RAGE was well tolerated in these early cohorts, with no clinically relevant deterioration in chest X-ray findings, pulmonary function tests or systemic inflammatory markers. The delivery approach is of interest because inhaled siRNA may eventually be explored for other inflammatory lung diseases as well. An orthopaedic surgeon reading early research on inflammatory pathways should note that this was a small early-phase study and it was not designed to show improvement in asthma symptoms or fewer exacerbations, so clinical efficacy remains unproven.

Source: O’Carroll M et al. Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial. Nature Medicine. Published online 9 September 2026. DOI: 10.1038/s41591-026-04607-z. PMID 42717034. Checked 15 September 2026. Access: full article on the publisher’s website and PubMed record; no published correction or retraction was identified in the checked records.

← More General Medical Discoveries

Polish version

Content prepared by: Tomasz Poboży - orthopaedic surgeon.